Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, chemical insults, radiation, tissue injury and importantly cancer. Fibrosis is often a life-limiting condition as it significantly reduces the organ function or in case of the bone marrow, the blood production. Established fibrosis is non-reversible. Thus, the progression of fibrosis needs to be halted in an early stage. Myelofibrosis (MF) is an incurable blood cancer and the prototypic example of progressive development of bone marrow fibrosis. The bone marrow morphology in patients with MF suggests that there is a stepwise evolution from an initial pre-fibrotic phase to a fibrotic phase. However, the initial changes in the pre-fibrotic phase are not well understood and no specific markers for the early diagnosis have been defined. One major shortcoming is that specific anti-fibrotic therapies related to blood cancer do not exist. The only potentially curative option is an allogeneic stem cell transplant (ASCT). However, the majority of patients is not eligible for this high-risk procedure and the outcome is unpredictable. So far, all FDA approved therapeutic strategies focus on eliminating the malignant hematopoietic clone but not on the actual fibrosis-driving cells and pro-fibrotic stimuli. We identified disease-specific mechanisms in the fibrosis-driving cells as protagonists of fibrosis.
We demonstrated that fibrosis-driving cells are the long-sought biomarker and therapeutic target in bone marrow fibrosis related to. blood cancer. We believe that predictive biomarkers which at the same time act as therapeutic targets are the unmet need in the diagnosis and treatment of fibrosis related to blood cancer.